Here are the DEF 14A proxy statements from Inhibitor Theraptics Inc (INTI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow INTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INTI filings page.
Inhibitor Therapeutics, Inc. is holding a completely virtual annual stockholders meeting on September 15, 2026 at 10 a.m. Eastern via webcast. Holders of common stock as of July 20, 2026 (when 173,791,968 shares were outstanding) may vote.
Stockholders are asked to elect six incumbent directors, ratify Cherry Bekaert LLP as auditor for 2026, approve the 2025 Equity Incentive Plan, approve executive compensation on an advisory basis, choose the frequency of future say-on-pay votes, and authorize possible adjournment to solicit additional proxies. The 2025 plan reserves up to 20,000,000 shares plus an annual evergreen increase through 2035 and includes multiple award types.
The CEO’s annual base salary is $598,000, and the interim CFO’s base salary is $200,000. Cherry Bekaert billed $72,650 in audit fees and $6,825 in tax fees for 2025. The board recommends voting for all director nominees, all management proposals, and a three‑year say‑on‑pay frequency.